There was no significant difference between colorectal cancer patients with PIK3CA mutations and wt PIK3CA in PR/CR rate to the last line of FDA-approved therapy (1/18 [6%] vs. 0/37 [0%]; p=0.34) (Table 3). Here, PIK3CA is linked to colorectal cancer.